Pfizer vaccine significantly less effective in kids 5-11: study
Registered Nurse Natasha McDannis inoculates Otto Linn-Walton, 8, with the first dose of the Pfizer-BioNTech COVID-19 vaccine for children five to 12 years at NYC Health + Hospitals Harlem Hospital, Thursday, Nov. 4, 2021, in New York. (AP Photo/Jeenah Moon)
ovp test
Male shot by female at Shreveport apartment
Class to create biodiverse backyard
Rules for outbursts at Caddo School Board Meeting
(The Hill) — The Pfizer coronavirus vaccine is significantly less effective in children ages 5-11 than it is in older kids, a new study finds, raising questions about the correct dose to give to the young.
The study from researchers at the New York State Department of Health found that vaccine effectiveness against COVID-19 infection among children 5-11 declined from 68 percent to just 12 percent over the period of Dec. 13 to Jan. 30.
Effectiveness was higher for those ages 12-17, declining from 66 percent to 51 percent over the same period.
Children under 12 receive a dose that is one-third the size given to those 12 and up, which could explain the drop in effectiveness.
The study notes that effectiveness for children aged 5-11 was better against severe disease and that vaccination is still recommended.
The vaccine’s effectiveness against hospitalization among children 5-11 declined from 100 percent to 48 percent, compared to 85 percent to 73 percent for older children.
The results highlight the challenges that vaccination for children has faced. Last month, Pfizer delayed the timeline for its vaccine for children under 5, saying more time was needed to test a third dose.
The dose being tested in children under 5 is even smaller.
“These results highlight the potential need to study alternative vaccine dosing for children and the continued importance layered protections, including mask-wearing, to prevent infection and transmission,” the study states.
Still, the analysis says vaccination should continue for children under 12, an area where rates have been lagging.
“At this time, efforts to increase primary vaccination coverage in this age group, which remains (less than) 25% nationally, should continue,” it says.
The findings also could complicate the debate about masking in schools, as many areas are removing their school mask mandates.
Asked about the results, a Pfizer spokesperson said the company is “confident in the protection and safety of our COVID-19 vaccine” and has a “robust booster research program for adolescents.”
